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Abstract
Background Germline mutations in the BRCA1 and BRCA2
genes have been shown to account for the majority of hereditary
breast and ovarian cancers. The purpose of our study was to
estimate the incidence and spectrum of pathogenic mutations in
BRCA1/2 genes in high-risk Czech families.
Methods A total of 96 Czech families with recurrent breast and/
or ovarian cancer and 55 patients considered to be at high-risk
but with no reported family history of cancer were screened for
mutations in the BRCA1/2 genes. The entire coding sequence
of each gene was analyzed using a combination of the protein
truncation test and direct DNA sequencing.
Results A total of 35 mutations in the BRCA1/2 genes were
identified in high-risk families (36.5%). Pathogenic mutations
were found in 23.3% of breast cancer families and in 59.4% of
families with the occurrence of both breast and ovarian cancer.
In addition, four mutations were detected in 31 (12.9%) women
with early onset breast cancer. One mutation was detected in
seven (14.3%) patients affected with both a primary breast and
ovarian cancer and another in three (33.3%) patients with a
bilateral breast cancer. A total of 3 mutations in BRCA1 were
identified among 14 (21.4%) women with a medullary breast
carcinoma. Of 151 analyzed individuals, 35 (23.2%) carried a
BRCA1 mutation and 9 (6.0%) a BRCA2 mutation. One novel
truncating mutation was found in BRCA1 (c.1747A>T) and two
in BRCA2 (c.3939delC and c.5763dupT). The 35 identified
BRCA1  mutations comprised 13 different alterations. Three
recurrent mutations accounted for 71.4% of unrelated
individuals with detected gene alterations. The BRCA1
c.5266dupC (5382insC) was detected in 51.4% of mutation
positive women. The mutations c.3700_3704del5 and
c.181T>G (300T>G) contributed to 11.4% and 8.6% of
pathogenic mutations, respectively. A total of eight different
mutations were identified in BRCA2. The novel c.5763dupT
mutation, which appeared in two unrelated families, was the only
recurrent alteration of the BRCA2 gene identified in this study.
Conclusion Mutational analysis of BRCA1/2 genes in 151 high-
risk patients characterized the spectrum of gene alterations and
demonstrated the dominant role of the BRCA1 c.5266dupC
allele in hereditary breast and ovarian cancer.
Introduction
Breast cancer (BC) is the most common malignancy affecting
western women. About 5% to 10% of all BC cases are due to
inheritance of a susceptibility allele, consistent with transmis-
sion in an autosomal dominant fashion, and a substantial pro-
portion of these are due to germline mutations of the two major
highly penetrant cancer susceptibility genes, BRCA1 (OMIM,
113705; GenBank, U14680.1) [1,2] and BRCA2  (OMIM,
600185; GenBank, U43746.1) [3-5]. Hereditary BC is char-
acterized by an early age of onset, high incidence of bilateral
disease and frequent association with ovarian cancer (OC).
An increased incidence of other malignancies, such as
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colorectal, prostate and pancreatic cancer is also observed
among BRCA1/2 mutation carriers [6-8]. The proportion of
described mutations in BRCA1  relative to BRCA2  varies
between populations. With the exception of a strong BRCA2
founder effect in Iceland [9], however, BRCA1 mutations are
generally more frequently reported. In the majority (>80%) of
families with BC and OC, the diseases are linked to the
BRCA1 gene. Conversely, in the majority (>75%) of families
with male and female BC, the disease is linked to BRCA2.
Among families with female BC only, proportions of diseases
due to mutations in BRCA1, BRCA2 and other genes are sim-
ilar [10].
A large number of distinct mutations, polymorphisms and
genetic variants of uncertain significance in the BRCA1 and
BRCA2 genes is described in the Breast Cancer Information
Core Database (BIC Database) [11]. The majority of mutations
known to be disease causing result in a truncated protein due
to frameshift, nonsense or splice site alterations. The spectrum
of mutations varies between populations, with some showing
a high frequency of unique mutations, for example in Italy
[12,13], whereas a small number of founder mutations is more
common in other ethnic groups. Notably, a single founder
mutation in BRCA2 (c.771_775del5; commonly referred to as
999del5) accounts for the majority of hereditary cancer cases
in Iceland [9], and three ancestral mutations (c.68_69delAG
and c.5266dupC in BRCA1  and c.5946delT in BRCA2;
185delAG, 5382insC and 6174delT, respectively) were iden-
tified in the vast majority of families with a history of BC and
OC in Ashkenazi Jews [14]. Population specific mutations
have also been described in the Netherlands [15], Sweden
[16], France [17], Spain [18] and other countries [19]. Two
BRCA1  founder mutations, c.5266dupC and c.181T>G
(300T>G), occur most frequently in countries of Central and
Eastern Europe [20-25], including the Czech Republic [26].
The aim of this study was to estimate the incidence, spectrum
and possible clustering of disease phenotypes associated
with BRCA1 and BRCA2 mutations in the Prague area and
Central Bohemia. The analysis was performed in families with
a history of BC/OC and in high-risk patients not selected on
the basis of their family history of cancer.
Materials and methods
Patients and families
Women with BC or OC considered to be at high risk of carry-
ing a BRCA1 or BRCA2 mutation were selected for genetic
testing between 1998 and 2003 at the Department of Oncol-
ogy and at the Department of Gynecology and Obstetrics of
the First Faculty of Medicine Charles University in Prague. The
testing was performed immediately after confirming the patho-
logic diagnosis. All patients had Czech ancestries and were
living in the Prague area and Central Bohemia. Patients were
selected from cancer families that met the following criteria in
first- or second-degree relatives: two cases of either BC diag-
nosed before the age of 50 or OC diagnosed at any age; and
three or more cases of breast or ovarian cancer diagnosed at
any age. A total of 60 families had a history positive for BC only
(HBC families), 4 families had OC only (HOC families), and 32
families had both breast and ovarian cancer (HBOC families).
Genetic material for analysis was obtained from the youngest
affected individual from each family. Genetic testing was fur-
ther offered to patients diagnosed with BC before the age of
36 (31 women) or with bilateral BC before the age of 51 (3
women) and patients with both primary breast and ovarian
cancer (7 women) or medullary breast carcinoma diagnosed
at any age (14 women), regardless of absence of reported
family history of cancer (non-familial patients). All women in the
study gave their informed consent prior to genetic testing. The
protocol of investigation was approved by the Ethical Commit-
tee at the First Faculty of Medicine.
DNA and RNA isolation
Genomic DNA was isolated from EDTA blood samples using
the Wizard genomic DNA purification kit (Promega, Madison,
USA), according to the manufacturer's instructions. Total RNA
was obtained from peripheral blood lymphocytes and reverse
transcribed into cDNA as described [27].
Screening for BRCA1 and BRCA2 mutations
Most disease-associated mutations lead to premature termina-
tion of protein translation. Mutations are classified as deleteri-
ous if they truncate either the BRCA1 protein at least 10
amino acids from the C-terminus or the BRCA2 protein at
least 110 amino acids from the C-terminus [28]. The nomen-
clature of mutations used is according to den Dunnen and
Paalman [29], with nucleotides numbered from the A of the
ATG translation initiation codon of GenBank reference
sequences U14680.1 for BRCA1 cDNA and U43746.1 for
BRCA2 cDNA. Original designations for BRCA1/2 mutations
commonly referred to in the literature are included for ease of
cross-referencing.
Mutational analysis was carried out by the protein truncation
test (PTT) and direct DNA sequencing. The entire coding
region of BRCA1 and BRCA2 was divided into overlapping
fragments with sizes of 880 to 1569 bp and amplified by PCR.
The PTT assay was used for pre-screening of amplified frag-
ments; the final analysis of identified gene alterations was
done by sequencing appropriate PCR fragments. Large exons
(exon 11 of BRCA1 and exons 10 and 11 of BRCA2) were
amplified on genomic DNA (exon 11 of BRCA1 and BRCA2
in three and four fragments, respectively; exon 10 of BRCA2
as a single fragment), whereas the remaining coding exons
were amplified by two-step PCR (nested PCR) from cDNA
(exons 2 to 10 and 12 to 24 of BRCA1 and exons 2 to 9 of
BRCA2 as single fragments; exons 12 to 27 of BRCA2 in two
fragments). Primer sequences used for amplification of
BRCA1  and  BRCA2  fragments were as described
[16,30,31].Available online http://breast-cancer-research.com/content/7/5/R728
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Amplifications were performed in 12.5 µl reaction mixtures
containing PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl2), 0.2 mM dNTPs, 0.4 µM of each primer, 0.5U
of LA Taq DNA polymerase (Takara Shuzo Co., Shiga, Japan)
and 30–50 ng of genomic DNA. Following initial denaturation
(at 93°C for 2 minutes), 32 cycles (at 93°C for 1 minute, at
58°C for 1 minute, and at 72°C for 4minutes) and final exten-
sion (at 72°C for 5minutes) were performed. In the nested
PCR procedure, a 2 µl aliquot of the reverse transcription
reaction was used in the first round of amplification with exter-
nal primers. A 1 µl aliquot of the first PCR reaction was
removed and used as a template with internal primers in the
second round of amplification. Reaction conditions and
cycling parameters were as described above.
PTT-analysis was carried out by incubating PCR fragments
(0.5 µl) in the TnT/T7 coupled transcription/translation system
(Promega, Madison, USA) containing 0.5 to 1.0 µCi of L-
[35S]methionine (Amersham Biosciences, Buckinghamshire,
UK) for 90 minutes at 30°C in a total volume of 3 µl. Labeled
protein products were analyzed on 12% SDS/polyacrylamide
minigels (Bio-Rad Laboratories, Hercules, USA). The gels
were fixed and prepared for fluorography by washing in
Amplify (Amersham Biosciences, Buckinghamshire, UK).
Dried gels were exposed for 24 to 48 h to X-ray film at -80°C.
DNA sequencing
PCR products that gave rise to truncated proteins by PTT
analysis were gel purified and directly sequenced in forward
and reverse directions using the BigDye 3.1 terminator cycle
sequencing kit in a model 310 automated DNA sequencer
(Applied Biosystems, Foster City, USA). Mutations detected
by RNA-based analysis were confirmed by DNA sequencing.
Each identified sequence alteration was confirmed by the anal-
ysis of a second blood sample.
Frequently occurring mutations at the beginning and at the
end of BRCA1 (c.68_69delAG, c.181T>G and c.5266dupC)
were identified by sequencing of RT-PCR fragments corre-
sponding to exons 2 to 8 and 18 to 24. Sequence analyses of
amplified genomic fragments containing the end of exon 11 in
BRCA1 and exons 17 and 20 in BRCA2 were done as direct
tests for other recurrent variants (c.4034delA in BRCA1 and
c.7910_7914del5 and c.8537_8538delAG in BRCA2)
known to occur in the Czech Republic and in populations of
Central and Eastern Europe. In addition, in families with nega-
tive results from mutation analysis and with a strong history of
cancer (families with three or more BC and/or OC cases),
short exons of BRCA1 and BRCA2 were further screened for
mutations by direct sequencing of RT-PCR fragments or by
radioactive heteroduplex analysis following the protocol
described by Gayther et al. [32] and Serova et al. [33].
Statistical analysis
Differences in mutation frequencies among groups of analyzed
families were statistically evaluated by the Chi-square test.
Results
Mutation analysis was performed in 96 women from BC/OC
families and in 55 non-familial patients. Analysis revealed 44
pathogenic cancer predisposing mutations, 6 of which have
been previously reported elsewhere [27]. Within 151 analyzed
individuals, 35 (23.2%) carried a BRCA1  mutation and 9
(6.0%) a BRCA2 mutation.
The BRCA1 mutations comprised 13 distinct alterations dis-
tributed widely across the coding sequence of the gene (Table
1). Twelve gene alterations caused a premature protein termi-
nation: eight were frame-shift alterations, with the majority of
small deletions and insertions occurring in stretches of mono-
nucleotide or dinucleotide repeats, and four were nonsense
mutations. The c.181T>G mutation leading to a substitution of
conserved cysteine 61 with glycine (p.Cys61Gly) in the RING
finger domain of the BRCA1 protein was the only missense
mutation identified in the gene.
Of the 10 BRCA1 mutations observed only once in our series,
the c.1747A>T nonsense mutation is a novel gene alteration
(not reported to the BIC by June 2004) found in family 397
with two cases of OC diagnosed at the ages of 39 and 43.
Four additional mutations (c.1016delA, c.3331C>T,
c.1127delA and c.2263G>T) belong to rare gene alterations
(with one to four entries in the BIC database), whereas the oth-
ers (c.68_69delAG, c.1687C>T, c.2411_2412delAG,
c.3756_3759delGTCT and c.4165_4166delAG) occur fre-
quently in various European regions, including Central Europe.
Three recurrent mutations were found in 25 (71.4%) of the 35
women with detected alterations in BRCA1. The mutation
c.5266dupC (5382insC) was a highly prominent mutation
detected in 18 patients, which accounted for 51.4% of all
identified alterations in BRCA1. The mutation
c.3700_3704del5 found in four families was the second most
commonly identified alteration, which contributed to 11.4% of
mutations detected in BRCA1. The mutation c.181T>G
(300T>G; p.C61G) identified in three families comprised
8.6% of detected mutations.
The BRCA2 mutations included eight different gene abnor-
malities (Table 2). All alterations were localized to exon 11 and
led to a truncated protein product: five were frameshift altera-
tions and three were nonsense mutations. The mutation
c.3939delC is a novel frameshift mutation, which results in a
termination of translation at codon 1313. This mutation was
detected in family 348 with two cases of OC diagnosed at the
ages of 46 and 58. Both the c.3076A>T nonsense mutation
(occurring in conjunction with the c.3075G>T missense muta-
tion) and the frameshift mutation c.5238dupT belong to rare,Breast Cancer Research    Vol 7 No 5    Pohlreich et al.
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Table 1
Pathogenic germline BRCA1 mutations in breast and ovarian cancer patients from the Prague area
Family no. Mutation description Method of 
detection
No. of cancers in a family and age at onset
Exon Traditional 
nomenclature
Approved 
nomenclature
Predicted effect Breast 
cancer 
(bilateral)
Mean age at 
diagnosis
Other cancers (age at onset)
F-24 2 c.187_188delAG c.68_69delAG p.Glu23fsX39 Sequencing 1 35 Colon (54)
F-111 5 c.300T>G c.181T>G p.Cys61Gly Sequencing 3 42 Stomach (51)
F-126 5 c.300T>G c.181T>G p.Cys61Gly Sequencing 2 45 -
F-252 5 c.300T>G c.181T>G p.Cys61Gly Sequencing 1 29 -
F-43 11 c.1135delA c.1016delA p.Lys339fsX340 PTT 2 41 Colon (50), lung (64)
F-361 11 c.1246delA c.1127delA p.Asn376fsX393 PTT 1 37 Ovarian (52, 54, 55)
F-21 11 c.1806C>T c.1687C>T p.Gln563X PTT 1 (1) 46 Ovarian (43), melanoma (53)
F-397 11 c.1866A>Ta c.1747A>Ta p.Lys583Xa PTT - - Ovarian (39, 43)
F-249 11 c.2382G>T c.2263G>T p.Glu755X PTT 4 53 Ovarian (41, 54)
F-61 11 c.2530_2531delAG c.2411_2412delAG p.Gln804fsX808 PTT 3 49 -
F-80 11 c.3450C>T c.3331C>T p.Gln1111X PTT 2 52 -
F-305 11 c.3819_3823del5 c.3700_3704del5 p.Val1234fsX1241 PTT 1 38 Leukemia (67), lung (65)
F-337 11 c.3819_3823del5 c.3700_3704del5 p.Val1234fsX1241 PTT 3 44 -
F-347 11 c.3819_3823del5 c.3700_3704del5 p.Val1234fsX1241 PTT 2 42 -
F-390 11 c.3819_3823del5 c.3700_3704del5 p.Val1234fsX1241 PTT 1 42 Lung (56), kidney (65)
F-164 11 c.3875_3878delGTCT c.3756_3759delGTCT p.Leu1252fsX1262 PTT 2 (1) 42 Ovarian (40, 43), stomach (?)
F-245 12 c.4284_4285delAG c.4165_4166delAG p.Ser1389fsX HDA 2 38 Ovarian (44, 50), kidney (75)
F-15 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 1 32 -
F-75 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 1 44 Ovarian (?, ?)
F-152 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 2 58 Ovarian (72)
F-185 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 3 51 Colon (?)
F-187 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 3 48 Ovarian (56)
F-194 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 4 43 Ovarian (52)
F-201 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 2 41 -
F-239 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 3 46 Ovarian (41), stomach (?)
F-243 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 3 (1) 42 -
F-261 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 2 29 -
F-265 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 3 (1) 52 Ovarian (?)
F-273 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 3 36 Ovarian (42), colon (51, 56)
F-331 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 1 (1) 31 Uterus (60), colon (64)
F-342 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 2 50 Ovarian (41), colon (?)
F-368 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 4 (2) 37 Ovarian (40), kidney 78)
F-370 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 2 49 Ovarian (55)
F-385 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 1 52 Ovarian (61), colon (83), 
melanoma (79)
F-387 20 c.5385dupC c.5266dupC p.Gln1756fsX1829 Sequencing 3 (1) 36 -
Position in cDNA is according to GenBank accession number U14680. aNovel mutations. HAD, heteroduplex analysis; PTT, protein truncation test.Available online http://breast-cancer-research.com/content/7/5/R728
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infrequently reported gene alterations. Other identified muta-
tions (c.2808_2811delACAA, c.3975_3978dupTGCT,
c.5645C>A and c.5682C>G) occur frequently throughout
Western Europe.
Recurrent mutations represented over two-thirds of all the
BRCA1 mutations identified in this series. By contrast, the
alterations in BRCA2 were mostly unique. The c.5763dupT
mutation, which causes a premature termination of translation
at codon 1923, appeared in two families and was the only
recurrent alteration of the BRCA2 gene identified in this study.
The mutation was first detected in family 67 with breast and
ovarian cancer diagnosed before the age of 50. In the second
unrelated family (F-327), only one affected woman who devel-
oped BC at the age of 32 was found. This gene alteration has
since been reported once in Western Europe, as indicated in
the BIC database.
Table 3 shows the prevalence of mutations in BC/OC families
and in non-familial risk patients who had no reported family his-
tory of cancer. Pathogenic mutations were revealed in 35
(36.5%) of the 96 analyzed families. The incidence of muta-
tions differed significantly between HBC (14/60; 23.3%) and
HBOC (19/32; 59.4%) families (p = 0.0006). Two mutations
were found in four HOC families.
Non-familial patients included a group of 31 women diag-
nosed with BC between ages 22 years and 35 years without
history of BC or OC in their family. Pathogenic germline muta-
tions in predisposing genes were detected in four (12.9%)
women. Three mutations were identified in BRCA1
(c.68_69delAG, c.181T>G and c.5266dupC) and one in
BRCA2 (c.5763dupT). Screening of seven patients with both
breast and ovarian cancer and no family history identified one
mutation (14.3%) in the BRCA1  gene (c.5266dupC). The
mutation c.5266dupC was also detected in a group of three
patients (33.3%) with bilateral BC.
A high incidence of medullary carcinoma has been reported
among women with BRCA1-associated BC [34]. We per-
formed the analysis of BRCA1  and  BRCA2  genes in 14
women with this histological tumor subtype and found three
truncating mutations (21.4%) in exon 11 of the BRCA1 gene.
The c.3331C>T nonsense mutation was detected once,
whereas the c.3700_3704del5 frameshift mutation was iden-
tified in two cases. No alteration in the BRCA2 gene was
found among these analyzed patients.
Discussion
In our study, 35 mutations in the BRCA1 and BRCA2 genes
were detected in 96 BC/OC families. In addition, we found
four pathogenic mutations in patients with early onset BC, one
mutation in a case of a bilateral BC, one mutation in a woman
with both BC and OC, and three mutations in women with a
medullary breast carcinoma. The majority of mutations identi-
fied in our study lead to protein truncations. Although short
coding exons of both BRCA1 and BRCA2 were analyzed by
either direct sequencing or heteroduplex analysis, only the
BRCA1 c.181T>G (c.300T>G; p.C61G) missense mutation
and  BRCA2  c.3075G>T (p.K1025N) missense alteration
(present in conjunction with the K1026X nonsense mutation)
of unknown clinical significance were observed. One novel
Table 2
Pathogenic germline BRCA2 mutations in breast and ovarian cancer patients from the Prague area
Family no. Mutation description Method of 
detection
No. of cancers in a family and age at onset
Exon Traditional 
nomenclature
Approved 
nomenclature
Predicted effect Breast cancer 
(bilateral)
Mean age at 
diagnosis
Other cancers (age 
at onset)
F-263 11 c.3036_3039delAC
AA
c.2808_2811delAC
AA
p.Lys936fsX958 PTT 3 (1) 41 -
F-279 11 c.3303G>T; 
3304A>T
c.3075G>T; 
3076A>T
p.Lys1025Asn; 
p.Lys1026X
PTT 1 50 Ovarian (47, 50)
F-348 11 c.4167delCa c.3939delCa p.Tyr1313fsX PTT - - Ovarian (46, 58), 
lung (?)
F-237 11 c.4203_4206dupT
GCT
c.3975_3978dupT
GCT
p.Ala1327fsX1331 PTT 2 38 Stomach (?)
F-298 11 c.5466dupT c.5238dupT pAsn1747fsX PTT 1 41 Ovarian (59)
F-304 11 c.5873C>A c.5645C>A p.Ser1882X PTT 3 61 Ovarian (49), colon 
(67)
F-49 11 c.5910C>G c.5682C>G p.Tyr1894X PTT 2 (1) 45 Lung (?)
F-67 11 c. 5991dupTa c.5763dupTa p.Ala1922fsX1923a PTT 1 48 Ovarian (49), 
esophagus (?)
F-327 11 c. 5991dupTa c.5763dupTa p.Ala1922fsX1923a PTT 1 32 -
Position in cDNA is according to GenBank accession number U43746. aNovel mutations. PTT = protein truncation test.Breast Cancer Research    Vol 7 No 5    Pohlreich et al.
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mutation was found in BRCA1 (c.1747A>T); two novel muta-
tions were identified in BRCA2  (c.3939delC and
c.5763dupT).
The prevalence of inherited BRCA1/2 mutations observed in
different studies varies according to the ethnic origin of
analyzed individuals, criteria of selection for genetic testing
and techniques used for mutational screening. Although the
techniques we applied in our study compromised our ability to
detect missense mutations in regions of the BRCA1/2 genes
screened only by PTT, at present the majority of reported mis-
sense alterations are difficult to interpret with respect to
potential clinical significance, as the effect of the amino acid
substitution on protein function is not yet well understood.
Conversely, most protein truncating BRCA1/2 mutations are
presumed to be pathogenic, thereby permitting women har-
boring such mutations to be provided appropriate clinical
counseling and management. Our study may not have
detected large genomic rearrangements encompassing
regions outside the primer sets used for RT-PCR amplification.
On the other hand, in the absence of rapid degradation of
aberrant transcripts by nonsense-mediated mRNA decay [35],
any rearrangements encompassing the exons within the
regions amplified from cDNA would have been observed as
aberrantly sized PCR products, as has also been found in
other studies [36]. Further, the prevalence of genomic rear-
rangements varies between populations. To our knowledge,
large deletions and rearrangements in BRCA1/2 genes have
not been reported in countries of Central and Eastern Europe.
In our series, analysis of truncated RT-PCR products and
sequencing of corresponding genomic fragments identified
one case with the rearrangement that involved exons 21 and
22 of the BRCA1 gene (Zikan, unpublished results). Despite
the limitations of our approach, the prevalence of mutations in
our group of high-risk families was comparable to that
observed in Central Europe [21,23,26]. Further, the distribu-
tion of germline BRCA1/2 mutations in our high-risk families is
consistent with a higher prevalence in the context of OC [10];
mutations were detected significantly more frequently in
HBOC and HOC families than in HBC families (58.3% of 36
versus 23.3% of 60; p = 0.0006).
Interestingly, both BRCA1 and BRCA2 mutationswere more
prevalent in families with OC (Table 3). Of the 27 BRCA1
mutations detected in high-risk families, 11 were present in
HBC families (18.3%), whereas 16 were identified in HBOC
and HOC families (44.4%). Of the eight mutations detected in
BRCA2, three were present in HBC families (5%), relative to
five in HBOC and HOC families (13.9%). This observation is
in contrast to observations in larger series of examined fami-
lies, where the risk of OC was significantly greater among
women with BRCA1  mutations compared to women with
BRCA2 mutations [10,37]. The higher prevalence of BRCA2
mutations among families with OC in our study may be due to
the preponderance of mutations identified in the ovarian can-
cer cluster region, and lend support to the increased risk of
OC suggested to be conferred by mutations within this region
relative to other BRCA2 mutations [38,39].
Table 3
Frequencies of BRCA1 and BRCA2 mutations in relation to the classification of patients and families
Classification Number of patients/
families
No. of mutations in 
BRCA1 (%)
No. of mutations in BRCA2 
(%)
No. of BRCA1 + BRCA2 
mutations (%)
Cases without a family history of breast and 
ovarian cancer
Breast cancer before 36 31 3 (9.7) 1 (3.2) 4 (12.9)
Bilateral breast cancer before 51 3 1 (33.3) - 1 (33.3)
Breast and ovarian cancer 7 1 (14.3) - 1 (14.3)
Medullary breast carcinoma 14 3 (21.4) - 3 (21.4)
Breast cancer families (HBC)
2 breast cancer cases 25 5 (20.0) 2 (8.0) 7 (28.0)
≥ 3 breast cancer cases 35 6 (17.1) 1 (2.9) 7 (20.0)
Total 60 11 (18.3) 3 (5.0) 14 (23.3)
Breast and ovarian cancer families (HBOC)
1 breast cancer and 1 ovarian cancer 5 1 (20.0) 2 (40.0) 3 (60.0)
≥ 3 breast and ovarian cancer cases 27 14 (51.9) 2 (7.4) 16 (59.3)
Total 32 15 (46.9) 4 (12.5) 19 (59.4)
Ovarian cancer families (HOC)
≥ 2 ovarian cancer cases 4 1 (25.0) 1 (25.0) 2 (50.0)
HBC, hereditary breast cancer; HBOC, hereditary breast and ovarian cancer; HOC, hereditary ovarian cancer.Available online http://breast-cancer-research.com/content/7/5/R728
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Gayther et al. [40] have reported that mutations in the 3' third
of the BRCA1 gene are associated with a lower proportion of
ovarian cancer. The border for this phenotype correlation was
located at exon 13, between codons 1435 and 1443. Further
studies provided proof for this genotype-phenotype
correlation [16,41], although other authors failed to replicate
this observation for BRCA1 mutations [17,20]. Despite the
higher occurrence of ovarian cancer in high-risk families with
mutations located in exons 2 to 12, the relative frequency (12/
37 cancer cases; 32.4%) did not differ significantly in our
study from the frequency of ovarian cancer (11/51 cancer
cases; 21.6%) in patients with mutations in exons 14 to 24 (p
= 0.25).
The surprising finding of our investigation was a high predom-
inance of recurrent mutations in the BRCA1 gene, which con-
tributed to a substantial proportion of hereditary BC and OC
cases. The three repeatedly occurring mutations in BRCA1
were detected in more than 56% of women with identified
alterations in BRCA1/2  genes and in more than 71% of
women with alterations in BRCA1. The most frequent muta-
tion was c.5266dupC (5382insC) found in 15 (15.6%) of 96
analyzed BC/OC families and in 18 (40.9%) of 44 BRCA1/2
mutation positive patients. The occurrence of this mutation is
comparable to that found in Polish [22,23,25,42] and Russian
[20] populations, but significantly higher than that described in
Germany [43] and Austria [21]. The c.5266dupC mutation is
the most prevalent BRCA1 alteration in Europe and a geo-
graphic distribution of this mutation is consistent with its Baltic
origin [19]. The c.5266dupC allele also occurs at a high fre-
quency (0.11%) in the Ashkenazi Jewish population [14],
although the 18 Czech patients carrying this gene defect did
not report an Ashkenazi Jewish heritage. The other two recur-
rent mutations detected in our group of patients,
c.3700_3704del5 and c.181T>G (300T>G), also belong to
gene alterations that have been repeatedly detected in the
Central European population [23-26].
The BRCA1 c.5266dupC and c.181T>G mutations are prev-
alent in Poland and in the Czech Republic, although spectra of
mutations display significant differences in these countries
[26,42]. The mutation c.4034delA (4153delA), contributing to
9.8% of mutations identified in BRCA1 in Poland [42], did not
occur either in our or in Moravian families [26]. We identified
10 unique mutations in BRCA1, which suggests that the
spectrum of alterations in this gene is more heterogeneous
than that reported in Poland [42].
In contrast to the BRCA1  gene, there were few recurrent
mutations within BRCA2. With the exception of the
c.5763dupT mutation detected in two unrelated individuals,
each alteration identified in BRCA2 was found in only one
family.
In a set of pathogenic mutations in BRCA1 identified in Brno
(Moravia) [26], the prevalence of the three most common
mutations (c.5266dupC, c.3700_3704del5 and c.181T>G)
was 37.3% (22/59), 13.6% (8/59) and 10.2% (6/59), respec-
tively, whereas in our group of patients, the prevalence of
these alterations was 51.4% (18/35), 11.4% (4/35) and 8.6%
(3/35). Small variations in the mutation spectra observed in
both studies may be caused by limited sample size and may
also reflect differences in the groups of patients selected for
genetic testing.
The occurrence of BRCA2 mutations was higher in Moravia
(33%; 29/88 of mutation positive patients) than in our study
(20.5%; 9/44 of mutation positive patients) and the spectrum
of genetic alterations was completely different [26]. The
c.7910_7914del5 (8138_8142del5) and
c.8537_8538delAG (8765_8766deAG) alterations found in
Brno in 7 (24.1%) of the 29 families with detected mutations
in BRCA2, were not present in our group of patients. On the
contrary, the mutation c.5763dupT, the only recurrent altera-
tion of the BRCA2 gene identified in our study, was not found
in Moravia. A high frequency of unique BRCA2 mutations may
be characteristic of the examined Prague area and Central
Bohemia, although the examination of a larger group of families
is required to obtain valid results.
The incidence of BRCA1/2 mutations in a group of Czech
women with early onset non-familial BC was 12.9% (4/31;
Table 3), whichsuggests that the age at diagnosis in patients
with a negative family history is an important indicator for the
presence of a pathogenic mutation and lends support to the
screening of BRCA1/2 genes in patients with early onset dis-
ease. In contrast to our findings, only 2% of non-familial
patients had pathogenic germline BRCA1 and BRCA2 muta-
tions in a group of patients in Great Britain who were diag-
nosed with BC at the age of 30 years or younger [44]. A
similarly low frequency of mutations was found in non-familial
patients in Spain and Iran [45,46]. In our study, all patients car-
ried the most common, easily detectable mutations of BRCA1
or BRCA2 that prevail in this region and can be associated
with early onset cancer. A larger set of patients with early
onset BC is currently under investigation to determine the inci-
dence of mutations in this risk group.
Medullary carcinoma of the breast is not common (2% to 3%)
in patients with BRCA2 mutations and those with no known
germline gene alteration [47]. In BRCA1-related BC, the inci-
dence of typical medullary carcinoma was 19% (6/32) in a
French study [34], 8% (4/49) in a Dutch study [48], but 0% in
a Swedish series of 40 BRCA1-associated tumors [49]. In our
study, one medullary carcinoma was identified in a group of 22
patients (4.5%) with BRCA1-related BC (F-252), whereas no
tumor of this histological type was found in seven women with
BRCA2-associated tumors. We did, however, find three germ-
line BRCA1 mutations in a set of 14 patients (21.4%) withBreast Cancer Research    Vol 7 No 5    Pohlreich et al.
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medullary breast carcinoma selected for examination regard-
less of the family history. These women did not belong to high-
risk families and did not fulfill common criteria for genetic test-
ing. One patient (Table 1; F-80) with a medullary carcinoma at
age 50 had a sister affected with BC at age 54 and the other
two (Table 1; F-305 and F-390) with medullary carcinomas at
ages 38 and 42, respectively, were without a family history of
breast or ovarian cancer. Our results are in agreement with
studies of Eisinger et al. [34] who tested 18 cases of medul-
lary carcinoma for mutations in BRCA1 gene and found two
(11%) harboring BRCA1 mutations. Interestingly, these cases
did not belong to high-risk families either. Indication of cases
with medullary carcinoma for BRCA1 testing, regardless of
the family history, may be helpful in mutation screening. Exam-
ination of a larger group of patients with this histological type
of carcinoma is required to determine the importance of this
morphological parameter more exactly.
Conclusion
Mutational analysis of BRCA1/2  genes in 151 high-risk
patients characterized the spectrum of gene alterations and
demonstrated the dominant role of the BRCA1 c.5266dupC
(5382insC) allele in hereditary breast and ovarian cancer. The
pre-screening of high-risk patients for the presence of this
allele, which accounted for more than 40% of all identified
gene alterations, and pre-screening for the presence of other
pathogenic, repeatedly occurring alleles (c.3700_3704del5
and c.181T>G), which contributed to about 16% of gene
defects, could enable rapid detection of a high percentage of
patients with hereditary cancer predisposition and, thus,
reduce the cost of mutation analysis in the Czech population.
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